Taken together, these findings indicate that mitochondrial defects induced by CDK9 inhibition not only trigger ROS generation and DNA damage but also establish an oxidative and pro‐survival/carcinogenic microenvironment, potentially leading to an insufficient in vivo response to CDK9i in KRAS‐mutant cancers. The gene discussed is KRAS; the disease is cancer.